Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LIVAGRAFT

Financiado

Cerrado

Improvement of the clinical applicability of tissue engineered vascular grafts...

Improvement of the clinical applicability of tissue engineered vascular grafts as new regenerative therapy for children with congenital cardiovascular malformations Currently available artificial graft prostheses for congenital disorders lack the capacity of growth and often require complex and reconstructive surgical interventions. As a consequence, repetitive and high-risk surgical interven... ver más

29/02/2016

UZH

199K€

Presupuesto del proyecto: 199K€

Líder del proyecto

University of Zurich No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-02-29 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UZH

199.32K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TECAS Towards Tissue Engineering Solutions for Cardiovascular Surg... 3M€ Cerrado

RTI2018-096320-B-C21 BIOINGENIERIA DE CONSTRUCTOS BASADOS EN BIOMATERIALES PARA L... 182K€ Cerrado

LAF-GRAFT An Investigation into the viability of employing lipoaspirat... 248K€ Cerrado

ESPOIR European clinical study for the application of regenerative... 7M€ Cerrado

CPP2021-008438 Nuevo injerto humano vascular descelularizado y re-endoteliz... 93K€ Cerrado

PRE2019-088735 BIOINGENIERIA DE CONSTRUCTOS BASADOS EN BIOMATERIALES PARA L... 98K€ Cerrado

Líder del proyecto

University of Zurich No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 199K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Currently available artificial graft prostheses for congenital disorders lack the capacity of growth and often require complex and reconstructive surgical interventions. As a consequence, repetitive and high-risk surgical interventions during childhood are inescapable, associated with increased morbidity and mortality. This not only raises enormous costs for the society, but compromises the quality of life of the young patients. Therefore, manufacturing Living Vascular Grafts is the ultimate goal for both cardiovascular researchers and clinicians. Tissue engineering is an opportunity to create prostheses that are vital, growing, adaptive, and autologous and show optimal functionality. Such in-vitro tissue-engineered vascular grafts have demonstrated functionality and growth as pulmonary replacement in lambs. However, classical tissue engineering using autologous cells, necessitates invasive cell harvesting from the patient, time consuming cell expansion and production of the patient-specific graft. As the living cellular component of the grafts inherently limits clinical applicability, an accelular equivalent with corresponding strength, growth, and regenerative capacity, would provide an attractive alternative for the living tissue-engineered vascular grafts. Therefore, my goal is to improve the clinical applicability of the tissue-engineered pulmonary grafts by decellularizing them, therewith creating novel off-the-shelf constructs for children with congenital cardiovascular malformations. The in-vivo recellularization capacity of these accelular tissue-engineered pulmonary grafts will be evaluated in a pre-clinical animal model to demonstrate their potential to grow with the recipient. These innovative alterations to create unlimited off-the-shelf grafts will speed up the clinical translation of this novel concept. It will inherently favor the wellbeing of patients by reducing waiting time and avoiding reoperations, in addition to a reduction in health costs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores